---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-008486"
form_type: "8-K"
ticker: "LMMY"
cik: "0001939937"
company_name: "Exousia Bio, Inc."
filed_at: "2025-11-17T23:59:59+00:00"
generated_at: "2026-05-16T19:24:25.144564+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# LAMY acquires Exousia Ai in reverse merger; appoints Matthew Dwyer as sole officer and director

## Summary
- Closed acquisition of Exousia Ai, issuing 62,223,000 shares of common stock to Exousia Ai shareholders.
- Zhang Shengwu resigned as sole officer/director; Matthew Dwyer appointed as replacement effective November 17, 2025.
- Exousia Ai is a clinical-stage biotech developing plant-based exosome therapies, initially for oncology.
- Exousia Ai received FDA Orphan Drug Designation in November 2025 for its exosome-based glioblastoma multiforme (GBM) treatment.
- The Company adopts Exousia Ai's business plan and expects to use its proprietary exosome loading technology.

## SEC filing metadata
- accession: 0001683168-25-008486
- form_type: 8-K
- ticker: LMMY
- cik: 0001939937
- company_name: Exousia Bio, Inc.
- filed_at: 2025-11-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 5.01, 2.01, 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1939937/000168316825008486/0001683168-25-008486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1939937/000168316825008486/lamy_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-008486
- JSON: https://secwatch.observer/filing/0001683168-25-008486.json
- Plain text: https://secwatch.observer/filing/0001683168-25-008486.txt

## Source-grounded claims
- claim_id: 34a9d3864b95fd55150ace47281400cc13cba9f3
  claim: Exousia Bio, Inc. completed an acquisition involving Exousia Ai, Inc. for 62,223,000 shares of Company common stock (closed 2025-11-17).
  evidence_excerpt: of the issued and outstanding capital stock of Exousia Ai, with Exousia Ai becoming the Company’s wholly-owned subsidiary, in consideration of the Company’s issuing a total of 62,223,000 shares of Company common stock (the “Acquisition Shares” ) to the shareholders of Exousia Ai. On November 17, 2025, the parties closed the Reorganization Agreement, such that
  evidence_url: https://www.sec.gov/Archives/edgar/data/1939937/000168316825008486/0001683168-25-008486-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.